ERCC2 and cancer: Potentially actionable mutations that we identified include an ERCC2 nonsynonymous mutation that is indexed in both the Catalogue of Somatic Mutations in Cancer (COSMIC) [56] and OncoKB [45] and correlates strongly with increased sensitivity to cisplatin-based chemotherapy.